Counseling Points - December 2008 - (Page 12)

The Infusion Nurses Society (INS) is a national organization that fosters excellence in the domains of education, policy, practice, research, and organizational development.30 The INS develops and disseminates infusion therapy standards of practice, provides professional development and educational opportunities, and advances best practice through evidence-based research and professional certification. In addition, the INS promotes awareness of vascular access challenges associated with rheumatic diseases and provides its membership with accredited educational materials on the specific infusional drugs used in the treatment of RA.30 The INS website (www.ins1.org) is the access point for many resources for infusion clinicians and offers online symposia, educational on-demand and CD recordings, and CE webinars (the latter are soon to be available). Nurses can also obtain information on the Certified Registered Nurse Infusion (CRNI®) certification through the Infusion Nurses Certification Corporation (INCC).30 Local INS Chapters There are currently over 40 local INS chapters in various states across the United States. For a complete listing that includes contact phone numbers and email addresses, visit: www.ins1.org/i4a/pages/ Index.cfm?pageID=3361. Each year, the INS holds a national meeting and industrial exhibition, which is the largest forum devoted to the specialty of infusion therapy in the United States. The annual meeting offers over 100 educational sessions and scientific symposia that highlight the latest advances in infusion therapy.30 The INS has also partnered with the RNS to collaborate on issues common to both specialties. Another national meeting, the INS 2009 Fall National Academy, also offers advanced, critical information to nurses and allied health care professionals in the field of infusion therapy. All programs focus on the nine core content areas of infusion therapy. Nurses can explore the industrial exhibition at the meeting to see the latest infusion products and services that are currently available.30 References 1. Bingham CO III. Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2008;66:210-215. 2. Asquith D, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol. 2007;19:246-251. 3. Yazici Y, Abramson SB. Rheumatoid arthritis treatment and monitoring of outcomes—where are we in 2007? Controversies and opportunities. Bull NYU Hosp. 2007;65:300-305. 4. Rheumatoid arthritis drugs in development. Accessed November 13, 2008 at www.mayoclinic.com/health/rheumatoid-arthritis-drugs/AR00041. 5. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;21:2167-2179. 6. Keystone E, van der Heijde D, Manson D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58:3319-339. 7. Kay J, Matteson E, Dasgupta B. et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Arthritis Rheum. 2008;58:964-975. 8. Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2006; 54:2793-2806. 9. Ostergaard M, Baslund B, Rigby We, et al. Ofatumumab, a human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis: Early results from an ongoing, double-blind randomized, placebo controlled clinical trial (Abstract 2086). Arthritis Rheum. 2007;56(Suppl 9):S793-S794. 10. Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008;58:61-72. 11. Clinicaltrials.gov. Atacicept. Accessed November 12, 2008 at www. clinicaltrials.gov/ct2/results?term=atacicept+rheumatoid+arthritis. 12. Dorner T, Burmester GR. New approaches of B-cell directed therapy: beyond rituximab. Curr Opin Rhumatol. 2008;20:263-268. 13. Genovese M, Filipowicz-Sosnowska A, Merrill J, et al. Differential responsiveness to belimumab (BmAb) in combination with standard of care therapy in RF+, TNFa-inhibitor and methotrexate partial responder subgroups of subjects with moderate-severe rheumatoid arthritis. Arthritis Rheum. 2005;52;(Suppl)195-201. 14. Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993; 82:1120-1126. 15. Metz S, Wiesinger M, Vogt M, et al. Characterization of the interleukin (IL)6 inhibitor IL-6-RFP: fused receptor domains act as high affinity cytokinebinding proteins. J Biol Chem. 2007; 282:1238-1248. 16. Smolen J, Beauliu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomized trial. Lancet. 2008;371:987-997. 17. Gutierrez-Roelens I, Lauwerys BR. Genetic susceptibility to autoimmune disorders: Clues from gene association and gene expression studies. Curr Mol Med. 2008;8:551-561. 18. Incyte’s JAK Inhibitor Demonstrates Rapid and Marked Clinical Improvement in Rheumatoid Arthritis Patients. [press release]. Accessed November 12, 2008 at http://investor.incyte.com/phoenix.zhtml?c=69764&p= IROL-NewsText&t=Regular&id=1217246&. 19. T h e A r t h r i t i s F o u n d a t i o n . A c c e s s e d N o v e m b e r 1 2 , 2 0 0 8 a t www.arthritis.org/. 20. MedlinePlus. Trusted Information for You. Accessed November 12, 2008 at http://medlineplus.gov/. 21. Johns Hopkins Arthritis Center. Accessed November 12, 2008 at www.hopkins-arthritis.org/. 22. Mayo Clinic. Rheumatoid Arthritis. Accessed November 12, 2008 at www.mayoclinic.com/health/rheumatoid-arthritis/DS00020. 23. McNeil MEA. The First Year: Rheumatoid Arthritis. New York, NY: Marlowe & Company. 2005. 24. American College of Rheumatology. Patient Assistance Programs for Rheumatology-Related Drugs. Accessed November 12, 2008 at www.rheumatology.org/public/acrast.asp. 25. RxAssist. Patient Assistance Program Center. Accessed November 12, 2007 at www.rxassist.org/. 26. Partnership For Prescription Assistance. Accessed November 12, 2008 at www.pparx.org/Intro.php. 27. Partnership For Prescription Assistance Kids. Accessed November 12, 2008 at http://kids.pparx.org/. 28. The American College of Rheumatology. Accessed November 12, 2008 at www.rheumatology.org/. 29. Rheumatology Nurses Society. Accessed November 12, 2008 at www. rns-network.org/. 30. Infusion Nurses Society. Accessed November 12, 2008 at www.ins1.org/. COUNSELING POINTS™ 12 http://www.ins1.org http://www.Clinicaltrials.gov http://www.clinicaltrials.gov/ct2/results?term=atacicept rheumatoid arthritis http://www.clinicaltrials.gov/ct2/results?term=atacicept rheumatoid arthritis http://www.ins1.org/i4a/pages/Index.cfm?pageID=3361 http://www.ins1.org/i4a/pages/Index.cfm?pageID=3361 http://investor.incyte.com/phoenix.zhtml?c=69764&p=IROL-NewsText&t=Regular&id=1217246& http://investor.incyte.com/phoenix.zhtml?c=69764&p=IROL-NewsText&t=Regular&id=1217246& http://www.arthritis.org/ http://medlineplus.gov/ http://www.hopkins-arthritis.org/ http://www.mayoclinic.com/health/rheumatoid-arthritis/DS00020 http://www.rheumatology.org/public/acrast.asp http://www.rxassist.org/ http://www.pparx.org/Intro.php http://kids.pparx.org/ http://www.rheumatology.org/ http://www.rns-network.org/ http://www.rns-network.org/ http://www.mayoclinic.com/health/rheumatoid-arthritis-drugs/AR00041 http://www.ins1.org/

Table of Contents Feed for the Digital Edition of Counseling Points - December 2008

Counseling Points - December 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.